SPECIAL NOTICE
B -- Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals
- Notice Date
- 6/2/2010
- Notice Type
- Special Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- HHS-FDA-RFI-1072892
- Archive Date
- 6/22/2010
- Point of Contact
- Tara R. Hobson, Phone: 3018279691, Doreen Williams,
- E-Mail Address
-
Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov
(Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Description: Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals This is a RFI to determine the availability and capability of small businesses (i.e., certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and woman-owned small businesses) for Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals. This information is being sought for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Food and Drug Administration (FDA). No official solicitation exists; therefore, please do not request a copy of a solicitation. If in the future an official solicitation is released, there is no guarantee that sources responding to this will be included on the source list. No telephone inquiries will not be accepted. Draft Scope of Work: This requirement is to develop a DNA microarray that detects the diversity, antibiotic resistance, and presence of probiotics and food additives important to the FDA in human samples. The role of Affymetrix (and only Affymetrix) is essential to the production of the chip. The chip will be used by various parts of the FDA to evaluate the importance of different probiotics as well as the diversity of the human gut microbiome. CLIN 0001- MyGeneChip 49-4 Format MaskFree for Custom Cartridge Arrays CLIN 0002- MyGC 49-4F Array(need MaskFree) for Custom Cartridge Arrays Draft Specifications: • Chip will have three majors parts. o Antibiotic Resistance o Diversity (by 16S) o Presence of probiotics We may anticipate a firm fixed price purchase order. Viable parties shall provide the following: Part A. Capabilities and Technical Experience - Provide a capability statement describing how your company would provide Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals as provided in the Draft Scope of Work. Part B. Size of Business- Please provide your business size and submit copies of any documentation such as letters or certificates to indicate the firm's status. Part C. Organizational Conflict of Interest (OCI) - If any, provide disclosure of business activities of your company, your affiliates, your team members and affiliates of your team members which create either a conflict of interest or the appearance of a conflict of interest in the Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals. Part D. Cost Estimate - Provide a cost estimate in accordance with FAR Part 10, Market Research for Metagenomic Microarray Development for Gene Discovery of Enteric Pathogens and Community Analysis of Gastrointestinal Commensals. Part E. Small Business - Describe your ability to meet the requirements in accordance with 52.219.14 - Limitation on Subcontracting. Responses shall be:  identified with the RFI number ;  no more than ten (10) pages in length;  not submit marketing materials;  submitted to the email as indicated above. FDA makes no implied or in fact contract by issuing this RFI. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the FDA's view of the information received.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/HHS-FDA-RFI-1072892/listing.html)
- Record
- SN02165993-W 20100604/100602235009-b8f8bb988f4daae197c70b0c65148e8f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |